STI Stock Trade Intelligence
DXB

DIMERIX LIMITED

Health Care · ASX:DXB
$0.1950
▼ -2.50%
Market cap
$117M
Turnover
$147,414
Last price
$0.1950
Day change
-2.50%
Announcements
22
Range, past year
Open 0.475 · Low 0.155 · Now 0.195 · High 0.785
Open DXB in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

DXB momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
19/100
Wyckoff phase
Accumulation14d
Trend stage
Neutral
1 Day
-2.5%
1 Week
-11.4%
1 Month
-11.4%
1 Year
-59.4%
RSI
39
Avg daily range
7.0%

DIMERIX LIMITED scores 19 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 14 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

What stands out
  • Trend R² 0.81 — highly linear uptrend
Points to watch
  • 60d drawdown -38.1%
  • High volatility (ATR 7.0%)
  • Risk rating: Very High
  • Composite downside risk elevated
DXB appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

DXB announcements

Recent price-sensitive releases.
  • 2026-10-29 Dimerix Quarterly Activities Report and Appendix 4C Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-10-23 New Data Supports Biological Rationale for DMX-200 in FSGS Company Presentation | Progress Report
  • 2026-10-16 DMX-200 First 100 Patients Complete Phase 3 Trial Treatment Progress Report
  • 2026-10-05 First Patient Reaches Four Years in DMX-200 Clinical Program Progress Report
  • 2026-09-23 Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility Progress Report | Debt Facility
  • 2026-09-14 Dimerix DMX-652 Granted Mexican Composition of Matter Patent Progress Report
  • 2026-09-04 Dimerix Secures A$34 Million Non-Dilutive Funding Facility Trading Halt Lifted | Debt Facility
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.